Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ben Tran

Showing results (131-140 of 170) with videos related to

Pageof 17
Sort By:
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 17, 2019
Long-Term Follow-up and Outcomes of Retreatment in an Expanded 50-Patient Single-Center Phase II Prospective Trial of <sup>177</sup>Lu-PSMA-617 Theranostics in Metastatic Castration-Resistant Prostate CancerJohn Violet, Shahneen Sandhu, Amir Iravani, et al.
European Urology|December 26, 2021
Stereotactic Radiotherapy and Short-course Pembrolizumab for Oligometastatic Renal Cell Carcinoma-The RAPPORT TrialShankar Siva, Mathias Bressel, Simon T Wood, et al.
Clinical Colorectal Cancer|March 18, 2021
Multicohort Retrospective Validation of a Predictive Biomarker for Topoisomerase I InhibitorsKoji Ando, Al Ozonoff, Shin-Yin Lee, et al.
Investigational New Drugs|May 7, 2013
A phase I study of the oral gamma secretase inhibitor R04929097 in combination with gemcitabine in patients with advanced solid tumors (PHL-078/CTEP 8575)Suzanne Richter, Philippe L Bedard, Eric Xueyu Chen, et al.
The Journal of Urology|December 27, 2022
Characterization of Patients With Metastatic Renal Cell Carcinoma Experiencing Complete Response to First-line Therapies: Results From the International Metastatic Renal Cell Carcinoma Database ConsortiumKosuke Takemura, Vishal Navani, Matthew S Ernst, et al.
JCO Precision Oncology|August 29, 2024
Patient Experience of Complex Genomic Sequencing Exploring Patient Preference, Barriers, and Enablers for DeliveryKortnye Smith, Sophie O'Haire, Benjamin Markman, et al.
The New England Journal of Medicine|May 14, 2015
Randomized trial of TAS-102 for refractory metastatic colorectal cancerRobert J Mayer, Eric Van Cutsem, Alfredo Falcone, et al.
BJU International|March 31, 2022
High-dose chemotherapy for relapsed germ cell tumours: outcomes in low-volume specialized centresElizabeth A Connolly, Andrew Weickhardt, Peter Grimison, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 9, 2025
Prognostic Value of Initial Imaging and PSA Change with [<sup>177</sup>Lu]Lu-PSMA-617 Radiopharmaceutical Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: A ProsTIC Registry AnalysisDavid C Chen, James P Buteau, Nathan Papa, et al.
Clinical Genitourinary Cancer|January 8, 2026
Attrition Rates in Metastatic Renal Cell Carcinoma (mRCC) Following First Line Immunotherapy-Based Treatment: Results From the International mRCC Database Consortium (IMDC)Audreylie Lemelin, Martin Zarba, Kosuke Takemura, et al.
Pageof 17

Showing results (131-140 of 170) with videos related to

Sort By:
Pageof 17
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 17, 2019
Long-Term Follow-up and Outcomes of Retreatment in an Expanded 50-Patient Single-Center Phase II Prospective Trial of <sup>177</sup>Lu-PSMA-617 Theranostics in Metastatic Castration-Resistant Prostate CancerJohn Violet, Shahneen Sandhu, Amir Iravani, et al.
European Urology|December 26, 2021
Stereotactic Radiotherapy and Short-course Pembrolizumab for Oligometastatic Renal Cell Carcinoma-The RAPPORT TrialShankar Siva, Mathias Bressel, Simon T Wood, et al.
Clinical Colorectal Cancer|March 18, 2021
Multicohort Retrospective Validation of a Predictive Biomarker for Topoisomerase I InhibitorsKoji Ando, Al Ozonoff, Shin-Yin Lee, et al.
Investigational New Drugs|May 7, 2013
A phase I study of the oral gamma secretase inhibitor R04929097 in combination with gemcitabine in patients with advanced solid tumors (PHL-078/CTEP 8575)Suzanne Richter, Philippe L Bedard, Eric Xueyu Chen, et al.
The Journal of Urology|December 27, 2022
Characterization of Patients With Metastatic Renal Cell Carcinoma Experiencing Complete Response to First-line Therapies: Results From the International Metastatic Renal Cell Carcinoma Database ConsortiumKosuke Takemura, Vishal Navani, Matthew S Ernst, et al.
JCO Precision Oncology|August 29, 2024
Patient Experience of Complex Genomic Sequencing Exploring Patient Preference, Barriers, and Enablers for DeliveryKortnye Smith, Sophie O'Haire, Benjamin Markman, et al.
The New England Journal of Medicine|May 14, 2015
Randomized trial of TAS-102 for refractory metastatic colorectal cancerRobert J Mayer, Eric Van Cutsem, Alfredo Falcone, et al.
BJU International|March 31, 2022
High-dose chemotherapy for relapsed germ cell tumours: outcomes in low-volume specialized centresElizabeth A Connolly, Andrew Weickhardt, Peter Grimison, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 9, 2025
Prognostic Value of Initial Imaging and PSA Change with [<sup>177</sup>Lu]Lu-PSMA-617 Radiopharmaceutical Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: A ProsTIC Registry AnalysisDavid C Chen, James P Buteau, Nathan Papa, et al.
Clinical Genitourinary Cancer|January 8, 2026
Attrition Rates in Metastatic Renal Cell Carcinoma (mRCC) Following First Line Immunotherapy-Based Treatment: Results From the International mRCC Database Consortium (IMDC)Audreylie Lemelin, Martin Zarba, Kosuke Takemura, et al.
Pageof 17